Efficacy and safety of Maraviroc in treatment-experienced patients. Personal report

被引：0
|
作者：
Dell'Isola, C. [1 ]
Manzillo, E. [1 ]
Aprea, L. [1 ]
Franco, A. [1 ]
Pizzella, T. [1 ]
Simioli, F. [1 ]
Izzo, C. M. [1 ]
机构：
[1] AORN D Cotugno, Div Infect Dis, Naples, Italy
来源：
INFECTION | 2010年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [1] PHARMACOECONOMIC ANALYSIS OF MARAVIROC IN TREATMENT-EXPERIENCED HIV PATIENTS IN BRAZIL
    Machado, M.
    Canella, M.
    Franco, E.
    Zajdenverg, R.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A119 - A119
  • [2] Safety and efficacy of dolutegravir and maraviroc plus background regimen in HIV-1 treatment-experienced participants
    Prakash, M.
    Huang, J.
    Lim, J.
    Koteff, J.
    Trezza, C.
    Griffith, S.
    Ait-Khaled, M.
    Wynne, B.
    Gartland, M.
    Clark, A.
    Aboud, M.
    [J]. HIV MEDICINE, 2016, 17 : 21 - 21
  • [3] Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
    Giaquinto, Carlo
    Mawela, Muthuhadini Patience
    Chokephaibulkit, Kulkanya
    Della Negra, Marinella
    Mitha, Ismail Haroon
    Fourie, Jan
    Fang, Annie
    van der Ryst, Elna
    Valluri, Srinivas Rao
    Vourvahis, Manoli
    Zhang-Roper, Rebecca Yanhui
    Craig, Charles
    McFadyen, Lynn
    Clark, Andrew
    Heera, Jayvant
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (05) : 459 - 465
  • [4] EFFICACY AND SAFETY OF ATAZANAVIR/RITONAVIR THERAPY IN A COHORT OF TREATMENT-EXPERIENCED PATIENTS
    Celesia, B. M.
    Coco, C.
    Frasca, M. C.
    La Rosa, R.
    Nigro, L.
    Bisicchia, F.
    Palermo, F.
    Nunnari, G.
    Mughini, M. T.
    [J]. INFECTION, 2011, 39 : S68 - S68
  • [5] Five-Year Safety Evaluation of Maraviroc in HIV-1-Infected Treatment-Experienced Patients
    Gulick, Roy M.
    Fatkenheuer, Gerd
    Burnside, Robert
    Hardy, W. David
    Nelson, Mark R.
    Goodrich, James
    Mukwaya, Geoffrey
    Portsmouth, Simon
    Heera, Jayvant R.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (01) : 78 - 81
  • [6] Evaluation of the Efficacy and Safety of Switching to Tenofovir, Emtricitabine, and Rilpivirine in Treatment-Experienced Patients
    Surgers, Laure
    Valin, Nadia
    Viala, Celine
    Boyd, Anders
    Fonquernie, Laurent
    Girard, Pierre-Marie
    Morand-Joubert, Laurence
    Meynard, Jean-Luc
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 (01) : E10 - E12
  • [7] Optimizing management of treatment-naive and treatment-experienced HIV+ patients: the role of maraviroc
    Poveda, Eva
    Soriano, Vincent
    [J]. HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2010, 2 : 51 - 58
  • [8] Renal safety of tenofovir in HIV treatment-experienced patients
    Izzedine, H
    Isnard-Bagnis, C
    Hulot, JS
    Vittecoq, D
    Cheng, A
    Jais, CK
    Launay-Vacher, V
    Deray, G
    [J]. AIDS, 2004, 18 (07) : 1074 - 1076
  • [9] Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
    Lorenzen, Thore
    [J]. HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2010, 2 : 151 - 156
  • [10] Efficacy and safety of dual therapy with Rilpivirine and boosted Darunavir in treatment-experienced HIV patients
    Pasquau, Juan
    de Jesus, Samantha
    Hidalgo-Tenorio, Carmen
    Arazo, Piedad
    Jose Crusells, Maria
    Jose Rios, Maria
    Lozano, Fernando
    de la Torre, Javier
    Tornero, Carlos
    Garcia-Vallecillos, Coral
    Verdejo, Guillermo
    Palacios, Zaira
    Samperiz, Gloria
    Jose Galindo, Maria
    Alberto Terron, Jose
    Garcia-Deltoro, Miguel
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
12345